CLL patients may get a break from daily pills

This study looks at whether people with chronic lymphocytic leukemia (CLL) who have been in remission for at least two years can safely stop taking their BTK inhibitor medication. The goal is to see how long they stay cancer-free without treatment, and whether stopping improves their quality of life and reduces side effects. About 45 participants will be followed to check if the cancer returns and if they can restart treatment later if needed.